Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Mol Med (Berl). 2020 Jun;98(6):789-803. doi: 10.1007/s00109-020-01927-6. Epub 2020 Jun 3.
To date, there is no licensed treatment or approved vaccine to combat the coronavirus disease of 2019 (COVID-19), and the number of new cases and mortality multiplies every day. Therefore, it is essential to develop an effective treatment strategy to control the virus spread and prevent the disease. Here, we summarized the therapeutic approaches that are used to treat this infection. Although it seems that antiviral drugs are effective in improving clinical manifestation, there is no definite treatment protocol. Lymphocytopenia, excessive inflammation, and cytokine storm followed by acute respiratory distress syndrome are still unsolved issues causing the severity of this disease. Therefore, immune response modulation and inflammation management can be considered as an essential step. There is no doubt that more studies are required to clarify immunopathogenesis and immune response; however, new therapeutic approaches including mesenchymal stromal cell and immune cell therapy showed inspiring results.
迄今为止，尚无针对 2019 年冠状病毒病（COVID-19）的许可治疗方法或批准疫苗，每天新发病例和死亡人数都在增加。因此，制定有效的治疗策略来控制病毒传播和预防疾病至关重要。在这里，我们总结了用于治疗这种感染的治疗方法。尽管抗病毒药物似乎在改善临床症状方面有效，但尚无明确的治疗方案。淋巴细胞减少症、过度炎症和细胞因子风暴随后导致急性呼吸窘迫综合征仍然是导致疾病严重程度的未解决问题。因此，免疫反应调节和炎症管理可以被认为是一个重要步骤。毫无疑问，需要更多的研究来阐明免疫发病机制和免疫反应；然而，包括间充质基质细胞和免疫细胞治疗在内的新的治疗方法显示出了令人鼓舞的结果。
